I hope that David gets his grant and can move forward quickly with this study.
Entest Biomedical Applying For NIH Grant For Studying Chemotherapy Resistance In Cancer Stems Cells
Article Date: 12 Feb 2010
Entest BioMedical Inc. (OTCBB: ENTB) is applying for a grant offered jointly between the National Cancer Institute (NCI) and the National Institute on Aging (NIA). Both NCI and NIA are part of the National Institutes of Health. The grant Entest is applying for will involve studying cancer stem cells, specifically looking for characteristics among cancer stem cells leading to chemotherapy resistance.
If approved, Entest could receive up to $500,000 in funding over a two year period. This research dovetails into Entest's immunotherapeutic cancer vaccine model, as immunotherapy could prove significant in overcoming chemotherapy resistance in tumor cells.
Entest's Chairman & CEO David Koos noted, "We are interested in isolating cancer stem cells, which are characteristically resistant to chemotherapeutic agents. By isolating these cancer stem cells, we believe a cancer vaccine can be produced with a high efficacy level."
Currently, the Company's researchers are examining animal tumors. This research coupled with the immunotherapeutic research in process should assist the Company in rapidly moving forward with the development of a more efficacious treatment for cancer tumors.
Source
Entest BioMedical Inc.
Bio-Matrix Scientific Group
Entest Biomedical Applying For NIH Grant For Studying Chemotherapy Resistance In Cancer Stems Cells
Article Date: 12 Feb 2010
Entest BioMedical Inc. (OTCBB: ENTB) is applying for a grant offered jointly between the National Cancer Institute (NCI) and the National Institute on Aging (NIA). Both NCI and NIA are part of the National Institutes of Health. The grant Entest is applying for will involve studying cancer stem cells, specifically looking for characteristics among cancer stem cells leading to chemotherapy resistance.
If approved, Entest could receive up to $500,000 in funding over a two year period. This research dovetails into Entest's immunotherapeutic cancer vaccine model, as immunotherapy could prove significant in overcoming chemotherapy resistance in tumor cells.
Entest's Chairman & CEO David Koos noted, "We are interested in isolating cancer stem cells, which are characteristically resistant to chemotherapeutic agents. By isolating these cancer stem cells, we believe a cancer vaccine can be produced with a high efficacy level."
Currently, the Company's researchers are examining animal tumors. This research coupled with the immunotherapeutic research in process should assist the Company in rapidly moving forward with the development of a more efficacious treatment for cancer tumors.
Source
Entest BioMedical Inc.
Bio-Matrix Scientific Group